Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership

Collaboration to focus on advancing innovative therapies across multiple disease areas, including weight loss.

Apr. 1, 2026 at 2:51pm

Got story updates? Submit your updates here. ›

Biocytogen Pharmaceuticals, a global biotechnology company, and Sihuan Pharmaceutical Holdings Group Ltd., a leading pharmaceutical company, have announced a strategic partnership. The collaboration will leverage Biocytogen's antibody discovery platform and Sihuan's drug development, manufacturing, and commercialization capabilities to advance innovative therapies, with a focus on weight loss.

Why it matters

This partnership combines the strengths of two major players in the pharmaceutical industry, potentially leading to the development of novel and effective treatments for various diseases, including the growing issue of obesity and weight-related health concerns.

The details

Under the agreement, Biocytogen will utilize its integrated platforms, including proprietary target-humanized mouse models, in vivo efficacy systems, and AI-driven antibody discovery, to support the development of novel antibody therapeutics. Sihuan Pharmaceutical will contribute its extensive capabilities in drug development, manufacturing, and commercialization. The collaboration aims to accelerate the advancement of promising molecules toward clinical and commercial success.

  • The strategic partnership was announced on April 1, 2026.

The players

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

A global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies.

Sihuan Pharmaceutical Holdings Group Ltd.

A leading international medical aesthetic and pharmaceutical company with a focus on innovation, an independent research and development technology platform, and a rich global product pipeline.

Got photos? Submit your photos here. ›

What they’re saying

“We are pleased to establish this strategic partnership with Sihuan Pharmaceutical. Leveraging our proprietary platforms, Biocytogen has built a comprehensive pipeline of next-generation therapeutic modalities, including bispecific and multispecific antibodies, ADCs, VHHs, and TCR-based therapeutics. This collaboration will further expand our joint efforts across diverse disease areas and further demonstrate strong industry recognition of our technology platforms.”

— Dr. Yuelei Shen, President and CEO of Biocytogen

What’s next

The partnership aims to accelerate the advancement of promising molecules toward clinical and commercial success, with a focus on weight loss and other disease areas.

The takeaway

This strategic partnership between Biocytogen and Sihuan Pharmaceutical combines the strengths of two leading pharmaceutical companies, leveraging innovative technologies and extensive capabilities to drive the development of novel therapies and address unmet medical needs, particularly in the area of weight management.